Motisort is the world’s first migration assay that enables sorting/isolation of cell based on migratory potential. Originally designed to tackle the menace of Metastasis in cancer drug discovery and disease management, they are increasingly being adopted in allied fields of research to address the gap where conventional migration assays are limited to.
Migration assay can be utilized to sort cells with highest migration capacity from a heterogeneous population, that mirrors the metastatic process in tumor biology.
Motisort and Metastasis: Problem Solved (See the application)
Motisort was invented to address the major challenge in cancer pathophysiology, with a complex interplay of cellular networks, poorly understood tumor microenvironment and a plethora of genomic information.
Motisort Assay Design
Tool for Phenotypic Drug Discovery (PDD): Multiple mechanistic pathways synchronously alter tumor cells that trigger the metastatic process in cancer progression. Despite the advancements in various drugs for cancer therapy, the 5-year survival rate for cancer patients initially diagnosed with metastatic disease remains abysmally low. Hence there is an active and growing interest in the discovery towards novel target pathways for anti-metastatics that can certainly improve the overall Progression-Free-Survival PFS in cancer patients.
Personalised Medicine In Cancer: Motisort™ is currently undergoing clinical trials for personalised medicine using patient derived organoids. Using patient derived organoids with hetereogenous tumor sample, Motisort™ can be used to precisely identify the drug that inhibits metastasis that can be co-related to drug response in patient.